BTG Plc

Boston Scientific signed an agreement to acquire UK-based BTG for $4.2bn. The deal is expected to close mid-2019 after antitrust clearance.

Boston Scientific announced a recommended offer to acquire BTG plc, a UK-based company specializing in minimally-invasive treatments for cancer and vascular diseases, for approximately £3.3 billion ($4.2 billion). The transaction is expected to close in the first half of 2019.

British healthcare company BTG Plc acquired U.S. medical device maker Novate Medical for $20 million upfront and up to $130 million in milestone payments. Novate developed the Sentry vascular device for preventing pulmonary embolism.